Trial record 19 of 21 for:
Open Studies | "Poliomyelitis"
A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome
This study is not yet open for participant recruitment.
Verified March 2012 by Biolab Sanus Farmaceutica
Sponsor:
Biolab Sanus Farmaceutica
Information provided by (Responsible Party):
Biolab Sanus Farmaceutica
ClinicalTrials.gov Identifier:
NCT01549847
First received: March 7, 2012
Last updated: March 8, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This protocol aims to assess of L-carnitine and piracetam to relieve weakness, muscle fatigue and muscle pain in patients with Postpoliomyelitis Syndrome.
| Condition | Intervention | Phase |
|---|---|---|
|
Postpoliomyelitis Syndrome |
Drug: L-carnitine and piracetam Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Therapeutic Effect of the Association of L-carnitine and Piracetam as an Adjuvant Therapy in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome |
Resource links provided by NLM:
Further study details as provided by Biolab Sanus Farmaceutica:
Primary Outcome Measures:
- Changes in Muscle Weakness [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Changes in fatigue [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Changes in muscle pain [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Changes in daytime sleepiness [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Changes in quality of life [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Changes in daily function [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Changes in depressive mood [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Changes in oxidative capacity in skeletal muscle [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- Occurrence of adverse events [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 120 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: L-carnitine and piracetam |
Drug: L-carnitine and piracetam
L-carnitine/piracetam (990mg/810mg) PO BID
|
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo PO BID
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with Postpoliomyelitis Syndrome diagnosis confirmed over a year;
- Electromyography test compatible with poliomyelitis;
- Preserved ability to swallow medication;
- Oral communication ability preserved;
- Preserved ability to perform pedaling test in at least one lower limb affected by Postpoliomyelitis Syndrome;
- Ability to understand information about the study and to document the decision about participating in the trial by signing the Informed Consent Form.
Exclusion Criteria:
- History of intolerance to L-carnitine or piracetam;
- Treatment with L-carnitine during the past 3 months;
- Treatment with piracetam or any other nootropics pyrrolidone derivatives, during the past three months;
- Anemia (hemoglobin reference range - men 13 to 17 g/dL and women 12 to 15 g/dL);
- High level of glycated hemoglobin (> 7.0%);
- Electrolyte imbalance (hypokalaemia - reference potassium concentration range: 3.5 to 5.6 mmol / L);
- Renal failure (creatinine reference range: 0.70 to 1.50 mg/dL);
- Urinary tract infection;
- Thyroid dysfunction (reference range: free T4: 0.54 to 0.67 mg/dL and TSH reference range: 0.5 to 5.5 μUI/mL) or usual treatment with thyroid hormone supplementation;
- Cardiomyopathy;
- Uncontrolled hypertension;
- Known or suspected autoimmune disease;
- Confirmed pregnancy, or plans to get pregnant during the trial;
- Depression or bipolar affective disorders with moderate to severe episodes within the last twelve months;
- Insulin-dependent diabetes mellitus;
- Treatment with anticoagulant drugs over two weeks (including non-steroidal anti-inflammatory drugs (NSAIDs), warfarin, phenprocoumon, heparin);
- Usual cocaine or alcohol use;
- Any other condition judged by the investigator as a possibility to interfere on the participant's decision to be part of the study or to accomplish investigation procedures.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01549847
Locations
| Brazil | |
| UNIFESP | Not yet recruiting |
| São Paulo, SP, Brazil | |
| Contact: Acary Souza Bulle Oliveira, MD, PhD | |
| Principal Investigator: Acary Souza Bulle Oliveira, MD, PhD | |
Sponsors and Collaborators
Biolab Sanus Farmaceutica
Investigators
| Principal Investigator: | Acary Souza Bulle Oliveira, MD, PhD | Federal University of São Paulo |
More Information
No publications provided
| Responsible Party: | Biolab Sanus Farmaceutica |
| ClinicalTrials.gov Identifier: | NCT01549847 History of Changes |
| Other Study ID Numbers: | CAR-PIR.11.01 |
| Study First Received: | March 7, 2012 |
| Last Updated: | March 8, 2012 |
| Health Authority: | Brazil: National Health Surveillance Agency |
Keywords provided by Biolab Sanus Farmaceutica:
|
Postpoliomyelitis Syndrome Piracetam L-Carnitine |
Additional relevant MeSH terms:
|
Poliomyelitis Postpoliomyelitis Syndrome Muscle Weakness Myelitis Central Nervous System Viral Diseases Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases |
Spinal Cord Diseases Neurodegenerative Diseases Neuromuscular Diseases Neuromuscular Manifestations Neurologic Manifestations Pathologic Processes Signs and Symptoms Carnitine Piracetam Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013